ResearcherAbramson Cancer CenterActive in the last 2 years
Phyllis A. Gimotty
Matched on ORCID iD 0000-0002-3850-9799; OpenAlex author ID A5013962604, A5055553979. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor … First author DOI 10.1158/1078-0432.ccr-25-3297↗
- Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28127↗
- THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28099↗
- The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
- Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jacob Edward Till · 3 shared papers, 2021–2026 · strength 0.53
- Paper Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP… DOI 10.1158/1078-0432.ccr-25-3297↗
- Paper Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.28127↗
- Paper THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.28099↗
- Erica L. Carpenter · 3 shared papers, 2021–2026 · strength 0.53
- Paper Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP… DOI 10.1158/1078-0432.ccr-25-3297↗
- Paper Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.28127↗
- Paper THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.28099↗
- Kenneth Zaret · 3 shared papers, 2021–2026 · strength 0.53
- Paper Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP… DOI 10.1158/1078-0432.ccr-25-3297↗
- Paper Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.28127↗
- Paper THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.28099↗
- Brianna M. Krusen · 1 shared paper, 2026 · strength 0.28
- Ann L. Oberg · 1 shared paper, 2026 · strength 0.28
- Shounak Majumder · 1 shared paper, 2026 · strength 0.28
- Peter James O'Dwyer · 2 shared papers, 2021–2022 · strength 0.25
- Shirsa Udgata · 2 shared papers, 2021–2022 · strength 0.25
- Bryson W. Katona · 2 shared papers, 2021–2022 · strength 0.25
- Mark H. O’Hara · 2 shared papers, 2021–2022 · strength 0.25
- Kim A. Reiss · 2 shared papers, 2021–2022 · strength 0.25
- Brinda Alagesan · 1 shared paper, 2019 · strength 0.07
- Arnaud Pommier · 1 shared paper, 2019 · strength 0.07
- Tobiloba E. Oni · 1 shared paper, 2019 · strength 0.07
- Robert Grützmann · 1 shared paper, 2019 · strength 0.07
- Michael Goggins · 1 shared paper, 2019 · strength 0.07
- Michael Anthony Hollingsworth · 1 shared paper, 2019 · strength 0.07
- Dannielle D. Engle · 1 shared paper, 2019 · strength 0.07
- Youngkyu Park · 1 shared paper, 2019 · strength 0.07
- Ralph H. Hruban MD · 1 shared paper, 2019 · strength 0.07
- Christian P. Pilarsky · 1 shared paper, 2019 · strength 0.07
- David Arthur Tuveson · 1 shared paper, 2019 · strength 0.07
- Kenneth H. Yu · 1 shared paper, 2019 · strength 0.07
- Hervé Tiriac · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.